Johnson & ​Johnson (JNJ.N) said ‌on Monday ​it ​will acquire ⁠biotech ​Firefly ​Bio for $1 billion ​in ​cash, as it ‌looks ⁠to expand ​its ​cancer ⁠drug pipeline.